Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MetaVia Inc. (MTVA : NSDQ)

• Company Description    MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $3.85 Daily Weekly Monthly 20 Day Moving Average: 7,731,790 shares Shares Outstanding: 5.16 (millions) Market Capitalization: $19.88 (millions) Beta: 0.59 52 Week High: $19.03 52 Week Low: $0.97 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 153.29% 140.92% 12 Week 142.14% 123.84% Year To Date -54.27% -68.66%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 545 Concord Avenue Suite 210 - Cambridge,MA 02138 USA ph: 857-702-9600 fax: 734-293-0444 ir@metaviatx.com http://www.metaviatx.com

• General Corporate Information    Officers Hyung Heon Kim - Chief Executive Officer; President and Director Andrew I. Koven - Chairman of the Board Marshall H. Woodworth - Chief Financial Officer Mark A. Glickman - Director Jason L. Groves - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 64132R503 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 5.16 Most Recent Split Date: 12.00 (0.09:1) Beta: 0.59 Market Capitalization: $19.88 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.85 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.78 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.19 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 80.05% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -172.92 12/31/25 - -202.17 09/30/25 - -229.48 ROA 03/31/26 - -89.39 12/31/25 - -91.89 09/30/25 - -105.28 Current Ratio 03/31/26 - 2.73 12/31/25 - 1.93 09/30/25 - 1.74 Quick Ratio 03/31/26 - 2.73 12/31/25 - 1.93 09/30/25 - 1.74 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 1.76 12/31/25 - 2.31 09/30/25 - 2.88 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©